GSK announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. to co-promote GSK‘s shingles vaccine, Shingrix, in China for an initial three-year period, with the potential to extend the partnership should all parties agree. Set to start on January 1, 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China – focusing on promoting the vaccine through its service network, which covers more than 30,000 vaccination points across the country. In partnership, GSK – as the license holder for the product – will co-promote Shingrix, the company said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GlaxoSmithKline (NYSE:GSK) Gains on £2.5B Deal for Shingles Vaccine in China
- GSK to sell 270M shares in Haleon
- Moderna (NASDAQ:MRNA) Gains on COVID-19 and Flu Shot Combination
- GSK price target raised to 1,585 GBp from 1,440 GBp at Morgan Stanley
- Scynexis recalling Brexafemme from market, placing temporary hold on studies